Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia (Q34044905)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

1 reference

based on heuristic

inferred from title

0 references

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

1

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Giovanni Martinelli

2

object named as

Giovanni Martinelli

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Aristoteles A N Giagounidis

14

object named as

Aristoteles Giagounidis

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jacques-Olivier Bay

6

object named as

Jacques-Olivier Bay

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

Elias J Jabbour

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Alfonso Quintás-Cardama

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Kiyoshi Ando

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Andrew Wei

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Stefanie Gröpper

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Cristina Papayannidis

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Kate Owen

10

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Laura Pike

11

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Nicola Schmitt

12

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Paul K Stockman

13

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

SPARK-AML1 Investigators

15

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

19 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

119

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

2611-2619

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

The treatment of elderly patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Independent prognostic factors for AML outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Modeling the temporal evolution of the spindle assembly checkpoint and role of Aurora B kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Prognostic factors in elderly patients with AML and the implications for treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Aurora kinases link chromosome segregation and cell division to cancer susceptibility

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

High expression of Aurora-B/Aurora and Ipll-like midbody-associated protein (AIM-1) in astrocytomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4132839

5 July 2018

Validity and reliability of the FACT-G scale for use in the older person with cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28113

21 January 2018

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28113

21 January 2018

Gene expression profiling of pediatric acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28113

21 January 2018

Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28113

21 January 2018

A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28113

21 January 2018

Interval estimation for the difference between independent proportions: comparison of eleven methods

1 reference

https://pubmed.ncbi.nlm.nih.gov/23605952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23605952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/23605952

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.28113

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34044905&oldid=1539611248"